OncLive - "Dr. Jagannath on Life Expectancy in Myeloma"

 – January 22, 2013 /Press Release/  –– 

Sundar Jagannath, MD, Director, Multiple Myeloma Program, The Tisch Cancer Institute at The Mount Sinai Medical Center, details recent advances that have impacted the life expectancy of patients with multiple myeloma. Fairly new drugs such as bortezomib, lenalidomide, dexamethasone, and thalidomide have moved life expectancy of all multiple myeloma patients from three years to five years, even for older patients. "These drugs have also moved the life expectancy of younger, transplant-eligible patients from five to seven years," Dr. Jagannath says. Learn more